During the past decade, Japanese Red Cross Kumamoto Hospital conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 9 clinical trials were completed, i.e. on average, 39.1% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 9 clinical trials were completed. i.e. 56.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Japanese Red Cross Kumamoto Hospital" #1 sponsor was "Bayer" with 8 trials, followed by "Boehringer Ingelheim" with 4 trials sponsored, "Pfizer" with 3 trials sponsored, "Arena Pharmaceuticals" with 2 trials sponsored and "Takeda" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Japanese Red Cross Kumamoto Hospital" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "Tokyo Medical and Dental University" with 2 trials as a collaborator and "Population Health Research Institute" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Japanese Red Cross Kumamoto Hospital" are "Ulcerative Colitis" (4 trials), "Endometriosis" (3 trials), "Chronic Kidney Disease" (2 trials), "Colorectal Cancer" (2 trials) and "Heart Failure" (2 trials). Many other conditions were trialed in "Japanese Red Cross Kumamoto Hospital" in a lesser frequency.

Most popular intervention types in "Japanese Red Cross Kumamoto Hospital" are "Drug" (23 trials), "Biological" (2 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Empagliflozin" (4 trials), "Etrasimod" (4 trials), "Vilaprisan (BAY1002670)" (3 trials) and "Guselkumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Japanese Red Cross Kumamoto Hospital" are 21 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Japanese Red Cross Kumamoto Hospital". undefined are not yet recruiting, 9 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Japanese Red Cross Kumamoto Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Japanese Red Cross Kumamoto Hospital, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".